M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
Sih Min Tan,Arpeeta Sharma,Nada Stefanovic,Derek Y.C. Yuen,Tom C. Karagiannis,Colin J. Meyer,Keith W. Ward,Mark E. Cooper,Judy B. de Haan +8 more
TL;DR: It is shown that dh404, at lower but not higher doses, significantly lessens diabetes-associated atherosclerosis with reductions in oxidative stress and proinflammatory mediators tumor necrosis factor-α, intracellular adhesion molecule-1, vascular cell adhesion molecules- 1, and monocyte chemotactic protein-1 (MCP-1).
Journal ArticleDOI
Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
Alejandra Gallardo-Godoy,Craig Muldoon,Bernd Becker,Alysha G. Elliott,Lawrence H. Lash,Johnny X. Huang,Mark S. Butler,Ruby Pelingon,Angela M. Kavanagh,Soumya Ramu,Wanida Phetsang,Mark A. T. Blaskovich,Mark E. Cooper +12 more
TL;DR: This work conducted a systematic activity–toxicity investigation by varying eight of the nine polymyxin amino acid free side chains, preparing over 30 analogues using a novel solid-phase synthetic route, and found many of the new compounds possessed equal or better antimicrobial potency compared to poly myxin B.
Journal ArticleDOI
Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial
Barbora de Courten,Barbora de Courten,Maximilian de Courten,Georgia Soldatos,Sonia L Dougherty,Nora E. Straznicky,Markus P. Schlaich,Karly C. Sourris,Vibhasha Chand,Jean L.J.M. Scheijen,Bronwyn A. Kingwell,Mark E. Cooper,Casper G. Schalkwijk,Karen Z. Walker,Josephine M. Forbes,Josephine M. Forbes +15 more
TL;DR: A diet that is low in AGEs may reduce the risk of type 2 diabetes by increasing insulin sensitivity and a restriction in dietary AGE content may be an effective strategy to decrease diabetes and cardiovascular disease risks in overweight individuals.
Journal ArticleDOI
An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria.
Alysha G. Elliott,Johnny X. Huang,Søren Neve,Johannes Zuegg,Ingrid A. Edwards,Amy K. Cain,Christine J. Boinett,Lars Barquist,Carina Vingsbo Lundberg,Jason A. Steen,Mark S. Butler,Mehdi Mobli,Kaela M. Porter,Mark A. T. Blaskovich,Sergio Lociuro,Magnus Strandh,Mark E. Cooper,Mark E. Cooper +17 more
TL;DR: An optimized peptide antibiotic with broad-spectrum in vitro activities, in vivo efficacy in multiple disease models against multidrug-resistant Gram-negative infections, and reduced toxicity is presented.
Journal ArticleDOI
Fluorescent Antibiotics: New Research Tools to Fight Antibiotic Resistance
TL;DR: This review discusses the preparation and biological evaluation of fluorescent antibiotics, focussing on how these reporters and assay methods can help elucidate resistance mechanisms and the potential utility of such probes for real-time in vivo diagnosis of infections.